The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma

doi:10.1158/2159-8290.CD-RW2019-116

AACR Publications

Register
Log in
My Cart

Main menu

Home
About
Articles
For Authors
Alerts
News
- Cancer Discovery News
- Journal Press Releases

AACR Publications

User menu

Register
Log in
My Cart

Search

Search for this keyword

Advanced search

Search for this keyword

Advanced Search

Home
About
Articles
For Authors
Alerts
News
- Cancer Discovery News
- Journal Press Releases

Research Watch

The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma

DOI: 10.1158/2159-8290.CD-RW2019-116 Published September 2019

Article
Info & Metrics

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: July 2019 to December 2019

	Abstract	Full-text HTML	PDF
Total	1143	223	0

Cited By

Article Information

Volume 9, Issue 9, pp. OF11

DOI

https://doi.org/10.1158/2159-8290.CD-RW2019-116

PubMed

31350326

Published By

American Association for Cancer Research

Print ISSN

2159-8274

Online ISSN

2159-8290

History

Published first July 26, 2019.

Article Versions

Previous version (July 26, 2019 - 06:09).
You are viewing the most recent version of this article.

Author Information

View Full Text

PreviousNext

September 2019
Volume 9, Issue 9

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma

Message Subject (Your Name) has forwarded a page to you from Cancer Discovery

Message Body (Your Name) thought you would be interested in this article in Cancer Discovery.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma

Cancer Discov September 1 2019 (9) (9) OF11; DOI: 10.1158/2159-8290.CD-RW2019-116

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma

Cancer Discov September 1 2019 (9) (9) OF11; DOI: 10.1158/2159-8290.CD-RW2019-116

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
- Abstract
- Notes
Info & Metrics

Cited By...

Research Watch

Mutations in Receptor Tyrosine Kinases Drive Histiocytic Disorders
Pembrolizumab Monotherapy Is Active in Metastatic Prostate Cancer
MYC Superenhancer–Nuclear Pore Binding Increases MYC-Transcript Export

Show more Research Watch

Immunotherapy

Tumor MHC-II Neoantigens Maintain CD8+ T-cell Antitumor Immunity
HSC-iNKT Cell Therapy May Be a Feasible Therapeutic Strategy
γ-Secretase Inhibitors Improve Multiple Myeloma BCMA CAR-T Therapy

Show more Immunotherapy

Home
Alerts
Feedback
Privacy Policy

Articles

OnlineFirst
Current Issue
Past Issues

Info For

Authors
Subscribers
Advertisers
Librarians
Reviewers

About Cancer Discovery

About the Journal
Editors
Journal Sections
Permissions
Submit a Manuscript

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Main menu

User menu

Search

The CAR-T Therapy Tisagenlecleucel Is Safe in Secondary CNS Lymphoma

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: July 2019 to December 2019

Cited By

Article Information

Article Versions

Author Information

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Research Watch

Immunotherapy

Articles

Info For

About Cancer Discovery